LA PERSISTENZA SOTTO TERAPIA PER LE IBD PREMIA USTEKINUMAB E VEDOLIZUMAB. UN’OTTIMA META-ANALISI DALL’AUSTRALIA. DA “AP&T” (FREE).
Meta-analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease Tsz Hong Yiu et al. Abstract Background: The expanding options in advanced therapies for ulcerative colitis (UC) and Crohn’s disease (CD) present challenges in treatment selection. Persistence analysis assesses drug durability in real-world settings, acting as a surrogate marker for medication efficacy and tolerance.…

